MétaCan
Menu
Back to cohort
Record W2949568582 · doi:10.1136/bmjopen-2018-025228

Evaluating probiotics for the prevention of ventilator-associated pneumonia: a randomised placebo-controlled multicentre trial protocol and statistical analysis plan for PROSPECT

2019· article· en· W2949568582 on OpenAlexafffundabout
Jennie Johnstone, Diane Heels‐Ansdell, Lehana Thabane, Maureen O. Meade, John C. Marshall, François Lauzier, Erick Duan, Nicole Zytaruk, Daphnée Lamarche, Michael G. Surette

Bibliographic record

VenueBMJ Open · 2019
Typearticle
Languageen
FieldMedicine
TopicNosocomial Infections in ICU
Canadian institutionsUniversité LavalSt. Michael's HospitalMcMaster UniversityPublic Health OntarioUniversity of Toronto
FundersCanadian Institutes of Health ResearchCanadian Frailty NetworkAcademic Medical Organization of Southwestern OntarioMcMaster University
KeywordsMedicineVentilator-associated pneumoniaRandomized controlled trialIntensive care medicinePneumoniaClinical trialIntensive careLactobacillus rhamnosusPublic healthPlaceboEmergency medicineProbioticIntensive care unitInternal medicineAlternative medicineNursing

Abstract

fetched live from OpenAlex

Introduction Ventilator-associated pneumonia (VAP) is the most common healthcare-associated infection in critically ill patients. Prior studies suggest that probiotics may reduce VAP and other infections in critically ill patients; however, most previous randomised trials were small, single centre studies. The Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) aims to determine the impact of the probiotic Lactobacillus rhamnosus GG on VAP and other clinically important outcomes in critically ill adults. Methods PROSPECT is a multicentre, concealed, randomised, stratified, blinded, controlled trial in patients ≥18 years old, anticipated to be mechanically ventilated ≥72 hours, in intensive care units (ICUs) in Canada, the USA and Saudi Arabia. Patients receive either 1×10 10 colony forming units of L. rhamnosus GG twice daily or an identical appearing placebo. Those at increased risk of probiotic infection are excluded. The primary outcome is VAP. Secondary outcomes are other ICU-acquired infections including Clostridioides difficile infection, diarrhoea (including antibiotic-associated diarrhoea), antimicrobial use, ICU and hospital length of stay and mortality. The planned sample size of 2650 patients is based on an estimated 15% VAP rate and will provide 80% power to detect a 25% relative risk reduction. Ethics and dissemination This protocol and statistical analysis plan outlines the methodology, primary and secondary analyses, sensitivity analyses and subgroup analyses. PROSPECT is approved by Health Canada (#9427-M1133-45C), the research ethics boards of all participating hospitals and Public Health Ontario. Results will be disseminated via academic channels (peer reviewed journal publications, professional healthcare fora including international conferences) and conventional and social media. The results of PROSPECT will inform practice guidelines worldwide. Trialregistration number NCT02462590 ; Pre-results.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.080
metaresearch head score (Gemma)0.127
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.114
Threshold uncertainty score0.425

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0800.127
Meta-epidemiology (narrow)0.0070.004
Meta-epidemiology (broad)0.0090.008
Bibliometrics0.0040.006
Science and technology studies0.0030.005
Scholarly communication0.0050.003
Open science0.0030.003
Research integrity0.0080.010
Insufficient payload (model declined to judge)0.1140.021

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.115
GPT teacher head0.493
Teacher spread0.378 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations32
Published2019
Admission routes3
Has abstractyes

Explore more

Same venueBMJ OpenSame topicNosocomial Infections in ICUFrench-language works237,207